Published in Adv Virol on July 08, 2012
Kaposi's sarcoma-associated herpesvirus K3 and K5 ubiquitin E3 ligases have stage-specific immune evasion roles during lytic replication. J Virol (2014) 0.90
Varicella-Zoster Virus and Herpes Simplex Virus 1 Differentially Modulate NKG2D Ligand Expression during Productive Infection. J Virol (2015) 0.81
Extended B cell phenotype in patients with myalgic encephalomyelitis/chronic fatigue syndrome: a cross-sectional study. Clin Exp Immunol (2016) 0.78
HSV-2 specifically down regulates HLA-C expression to render HSV-2-infected DCs susceptible to NK cell killing. PLoS Pathog (2013) 0.78
A nationwide population-based cohort study to identify the correlation between heart failure and the subsequent risk of herpes zoster. BMC Infect Dis (2015) 0.75
How Viruses Contribute to the Pathogenesis of Hemophagocytic Lymphohistiocytosis. Front Immunol (2017) 0.75
NK cell recognition. Annu Rev Immunol (2005) 14.40
Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature (1986) 9.73
Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med (1989) 7.52
The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature (2005) 7.18
HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature (1998) 7.12
Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol (2003) 6.95
Herpes simplex virus turns off the TAP to evade host immunity. Nature (1995) 5.93
ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity (2001) 5.42
Host immune system gene targeting by a viral miRNA. Science (2007) 5.10
A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes. Cell (1994) 4.70
Evolutionary struggles between NK cells and viruses. Nat Rev Immunol (2008) 3.79
Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells. Cell Host Microbe (2009) 3.59
A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity (1997) 3.43
Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins. J Virol (2000) 3.30
Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science (2000) 3.20
Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med (1998) 2.87
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci U S A (2006) 2.72
Downregulation of major histocompatibility complex class I by human ubiquitin ligases related to viral immune evasion proteins. J Virol (2004) 2.63
Inhibition of natural killer cell-mediated cytotoxicity by Kaposi's sarcoma-associated herpesvirus K5 protein. Immunity (2000) 2.53
Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA. Nat Immunol (2001) 2.43
Killer cell inhibitory receptors specific for HLA-C and HLA-B identified by direct binding and by functional transfer. Immunity (1995) 2.37
Promiscuity and the single receptor: NKG2D. Nat Rev Immunol (2007) 2.27
The class I MHC homologue of human cytomegalovirus inhibits attack by natural killer cells. Nature (1997) 2.22
Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity. J Exp Med (2003) 2.20
Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity (2007) 2.20
Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands. J Immunol (2007) 2.12
NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest (2009) 2.08
Surface NK receptors and their ligands on tumor cells. Semin Immunol (2006) 1.92
Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res (2004) 1.87
Cutting edge: the human cytomegalovirus UL40 gene product contains a ligand for HLA-E and prevents NK cell-mediated lysis. J Immunol (2000) 1.85
Human natural killer cell development and biology. Blood Rev (2005) 1.83
Down-regulation of NKG2D and NKp80 ligands by Kaposi's sarcoma-associated herpesvirus K5 protects against NK cell cytotoxicity. Proc Natl Acad Sci U S A (2008) 1.80
Immune evasion by Kaposi's sarcoma-associated herpesvirus. Nat Rev Immunol (2007) 1.78
Immune escape and exploitation strategies of cytomegaloviruses: impact on and imitation of the major histocompatibility system. Cell Microbiol (2004) 1.76
Down-regulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142. Biochem Biophys Res Commun (2006) 1.62
Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res (2007) 1.60
Human cytomegalovirus encodes an MHC class I-like molecule (UL142) that functions to inhibit NK cell lysis. J Immunol (2005) 1.59
Human cytomegalovirus immunity and immune evasion. Virus Res (2010) 1.58
HLA class I molecules are not transported to the cell surface in cells infected with herpes simplex virus types 1 and 2. J Immunol (1994) 1.53
Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis. Gene Ther (2004) 1.51
Immune evasion of natural killer cells by viruses. Curr Opin Immunol (2008) 1.51
Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. Eur J Immunol (2003) 1.46
Identification of NKp80, a novel triggering molecule expressed by human NK cells. Eur J Immunol (2001) 1.46
DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res (2007) 1.45
Modulation of natural killer cell cytotoxicity in human cytomegalovirus infection: the role of endogenous class I major histocompatibility complex and a viral class I homolog. J Exp Med (1998) 1.43
UL40-mediated NK evasion during productive infection with human cytomegalovirus. Proc Natl Acad Sci U S A (2002) 1.36
Varicella-zoster virus retains major histocompatibility complex class I proteins in the Golgi compartment of infected cells. J Virol (2001) 1.36
The switch from latent to productive infection in epstein-barr virus-infected B cells is associated with sensitization to NK cell killing. J Virol (2006) 1.35
Major histocompatibility complex class I molecules are down-regulated at the cell surface by the K5 protein encoded by Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8. J Gen Virol (2001) 1.34
Herpes simplex virus type 2 ICP47 inhibits human TAP but not mouse TAP. J Virol (1998) 1.33
Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR). Cancer Biol Ther (2009) 1.32
Molecular mechanisms of natural killer cell activation. J Innate Immun (2011) 1.27
Natural cytotoxicity receptors NKp30, NKp44 and NKp46 bind to different heparan sulfate/heparin sequences. J Proteome Res (2009) 1.27
DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases. J Immunol (2009) 1.24
An integrated view of the regulation of NKG2D ligands. Immunology (2009) 1.23
Intracellular retention of the MHC class I-related chain B ligand of NKG2D by the human cytomegalovirus UL16 glycoprotein. J Immunol (2003) 1.21
Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase. J Virol (2009) 1.20
Crystal structure of the MHC class I homolog MIC-A, a gammadelta T cell ligand. Immunity (1999) 1.19
Expression of ICP0 is sufficient to trigger natural killer cell recognition of herpes simplex virus-infected cells by natural cytotoxicity receptors. J Infect Dis (2007) 1.16
Modulation of natural killer cell activity by viruses. Curr Opin Microbiol (2010) 1.16
Structure of UL18, a peptide-binding viral MHC mimic, bound to a host inhibitory receptor. Proc Natl Acad Sci U S A (2008) 1.13
Regulation of immune cell function and differentiation by the NKG2D receptor. Cell Mol Life Sci (2011) 1.12
Population study of allelic diversity in the human MHC class I-related MIC-A gene. Immunogenetics (1999) 1.11
Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle. PLoS Pathog (2009) 1.11
B7-H6/NKp30 interaction: a mechanism of alerting NK cells against tumors. Cell Mol Life Sci (2011) 1.11
Structure of the human activating natural cytotoxicity receptor NKp30 bound to its tumor cell ligand B7-H6. J Exp Med (2011) 1.11
Differential effects of US2, US6 and US11 human cytomegalovirus proteins on HLA class Ia and HLA-E expression: impact on target susceptibility to NK cell subsets. Eur J Immunol (2003) 1.10
Involvement of activating NK cell receptors and their modulation in pathogen immunity. J Biomed Biotechnol (2011) 1.10
Role for major histocompatibility complex class I in regulating natural killer cell-mediated killing of virus-infected cells. Proc Natl Acad Sci U S A (1992) 1.09
Human herpesvirus 8-associated neoplasms: the roles of viral replication and antiviral treatment. Curr Opin Infect Dis (2011) 1.09
NKG2D ligand MICA is retained in the cis-Golgi apparatus by human cytomegalovirus protein UL142. J Virol (2009) 1.09
Human natural killer cells limit replication of herpes simplex virus type 1 in vitro. J Immunol (1985) 1.09
Recognition and prevention of tumor metastasis by the NK receptor NKp46/NCR1. J Immunol (2012) 1.09
Oxidative stress increases MICA and MICB gene expression in the human colon carcinoma cell line (CaCo-2). Biochim Biophys Acta (2001) 1.08
Herpes simplex encephalitis : from virus to therapy. Infect Disord Drug Targets (2011) 1.05
Immediate-early gene expression is sufficient for induction of natural killer cell-mediated lysis of herpes simplex virus type 1-infected fibroblasts. J Virol (1991) 1.04
The human natural cytotoxicity receptors (NCR) that induce HLA class I-independent NK cell triggering. Hum Immunol (2000) 1.03
Modulation of HLA expression in human cytomegalovirus immune evasion. Cell Mol Immunol (2007) 1.02
Non-synonymous variant (Gly307Ser) in CD226 is associated with susceptibility to multiple autoimmune diseases. Rheumatology (Oxford) (2010) 1.01
Studies of the cell lineage of the effector cells that spontaneously lyse HSV-1 infected fibroblasts (NK(HSV-1)). J Immunol (1982) 1.00
Human herpesvirus-6 enhances natural killer cell cytotoxicity via IL-15. J Clin Invest (1996) 0.99
Human herpesvirus-6A and -6B encode viral immunoevasins that downregulate class I MHC molecules. Virology (2007) 0.98
Cutaneous infections caused by Herpesviridae: a review. Arch Pathol Lab Med (2011) 0.98
Here today--not gone tomorrow: roles for activating receptors in sustaining NK cells during viral infections. Eur J Immunol (2010) 0.98
Ocular herpes simplex virus: how are latency, reactivation, recurrent disease and therapy interrelated? Future Microbiol (2011) 0.97
Natural killer cells: fighting viruses and much more. Nat Immunol (2011) 0.96
Innate and adaptive immunity against herpes simplex virus type 2 in the genital mucosa. J Reprod Immunol (2011) 0.95
A role for MHC class I down-regulation in NK cell lysis of herpes virus-infected cells. Eur J Immunol (2000) 0.94
Enhancement of natural killer cell cytotoxicity by the human herpesvirus-7 via IL-15 induction. J Immunol (1997) 0.93
IDO metabolite produced by EBV-transformed B cells inhibits surface expression of NKG2D in NK cells via the c-Jun N-terminal kinase (JNK) pathway. Immunol Lett (2011) 0.93
Mechanisms of tumor and viral immune escape from natural killer cell-mediated surveillance. J Innate Immun (2011) 0.93
Human Herpesvirus 8 (HHV8) sequentially shapes the NK cell repertoire during the course of asymptomatic infection and Kaposi sarcoma. PLoS Pathog (2012) 0.93
Infectious agents in human cancers: lessons in immunity and immunomodulation from gammaherpesviruses EBV and KSHV. Cancer Lett (2011) 0.92
Herpes simplex virus infection downmodulates NKG2D ligand expression. Scand J Immunol (2009) 0.91
EBV protein BNLF2a exploits host tail-anchored protein integration machinery to inhibit TAP. J Immunol (2011) 0.91
Expression of CD94/NKG2A and killer immunoglobulin-like receptors in NK cells and a subset of extranodal cytotoxic T-cell lymphomas. Blood (2000) 0.91
The human herpesvirus-7 (HHV-7) U21 immunoevasin subverts NK-mediated cytoxicity through modulation of MICA and MICB. PLoS Pathog (2011) 0.91
Comparison of plan quality and delivery time between volumetric arc therapy (RapidArc) and Gamma Knife radiosurgery for multiple cranial metastases. Neurosurgery (2014) 3.38
Risk factors for conversion to permanent ventricular shunt in patients receiving therapeutic ventriculostomy for traumatic brain injury. Neurosurgery (2011) 1.45
The relationship between INR and development of hemorrhage with placement of ventriculostomy. J Trauma (2011) 1.44
Acid-sensing ion channels in malignant gliomas. J Biol Chem (2003) 1.38
Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain. J Biol Chem (2010) 1.30
Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas. J Neurooncol (2003) 1.28
Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model. Neuro Oncol (2005) 1.26
Hitting a moving target: evolution of a treatment paradigm for atypical meningiomas amid changing diagnostic criteria. Neurosurg Focus (2008) 1.26
Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111. J Neurooncol (2009) 1.20
Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide. J Med Imaging Radiat Oncol (2011) 1.18
Surface expression of ASIC2 inhibits the amiloride-sensitive current and migration of glioma cells. J Biol Chem (2006) 1.15
Oncolytic viral therapy of malignant glioma. Neurotherapeutics (2009) 1.12
Predictors of distant brain recurrence for patients with newly diagnosed brain metastases treated with stereotactic radiosurgery alone. Int J Radiat Oncol Biol Phys (2007) 1.10
Brain metastases. Curr Probl Surg (2004) 1.07
The role of integrin alpha8beta1 in fetal lung morphogenesis and injury. Dev Biol (2009) 1.04
Initial treatment of melanoma brain metastases using gamma knife radiosurgery: an evaluation of efficacy and toxicity. Cancer (2004) 1.01
Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12. Cancer Gene Ther (2005) 1.01
A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. Arch Neurol (2010) 0.99
Herpes simplex virus oncolytic therapy for pediatric malignancies. Mol Ther (2009) 0.99
Genetically engineered herpes simplex viruses that express IL-12 or GM-CSF as vaccine candidates. Vaccine (2005) 0.98
Protein kinase C isoform antagonism controls BNaC2 (ASIC1) function. J Biol Chem (2002) 0.97
Preclinical evaluation of ex vivo expanded/activated γδ T cells for immunotherapy of glioblastoma multiforme. J Neurooncol (2010) 0.97
Targeting pediatric cancer stem cells with oncolytic virotherapy. Pediatr Res (2012) 0.92
Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma. Neuro Oncol (2009) 0.92
Prognostic relevance of cytochrome C oxidase in primary glioblastoma multiforme. PLoS One (2013) 0.91
Cation selectivity and inhibition of malignant glioma Na+ channels by Psalmotoxin 1. Am J Physiol Cell Physiol (2004) 0.90
Dexmedetomidine as rescue drug during awake craniotomy for cortical motor mapping and tumor resection. Anesth Analg (2006) 0.89
Hypoxia Moderates γ(1)34.5-Deleted Herpes Simplex Virus Oncolytic Activity in Human Glioma Xenoline Primary Cultures. Transl Oncol (2012) 0.89
Meta-analysis of hemorrhagic complications from ventriculostomy placement by neurosurgeons. Neurosurgery (2011) 0.87
Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of neuroblastoma. PLoS One (2013) 0.87
Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates. Hum Gene Ther Clin Dev (2014) 0.86
Acyclovir-resistant chronic verrucous vaccine strain varicella in a patient with neuroblastoma. Pediatr Infect Dis J (2008) 0.85
Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide. Radiat Oncol (2014) 0.84
Polymerase chain reaction for the rapid detection of cerebrospinal fluid shunt or ventriculostomy infections. Neurosurgery (2005) 0.83
Spontaneous and Engineered Compensatory HSV Mutants that Counteract the Host Antiviral PKR Response. Viruses (2009) 0.83
Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapy. Front Oncol (2013) 0.82
Prolonged treatment with bevacizumab is associated with brain atrophy: a pilot study in patients with high-grade gliomas. J Neurooncol (2015) 0.82
Stereotactic radiosurgical treatment of brain metastasis of primary tumors that rarely metastasize to the central nervous system. J Neurooncol (2012) 0.80
Preclinical evaluation of oncolytic δγ(1)34.5 herpes simplex virus expressing interleukin-12 for therapy of breast cancer brain metastases. Int J Breast Cancer (2012) 0.80
Ganciclovir transiently attenuates murine cytomegalovirus-associated renal allograft inflammation. Transplantation (2011) 0.78
Molecular cloning and characterization of human acid sensing ion channel (ASIC)2 gene promoter. Gene (2003) 0.78
Effects of G207, a conditionally replication-competent oncolytic herpes simplex virus, on the developing mammalian brain. J Neurovirol (2007) 0.78
Viral therapy of glioblastoma multiforme. Proc Natl Acad Sci U S A (2013) 0.78
Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1. PLoS One (2013) 0.78
The role of early resection vs biopsy in the management of low-grade gliomas. JAMA (2012) 0.77
Evaluation of the Safety and Biodistribution of M032, an Attenuated HSV-1 Virus Expressing hIL-12, After Intracerebral Administration to Aotus Non-Human Primates. Hum Gene Ther Clin Dev (2014) 0.77
Strategies for the rapid construction of conditionally-replicating HSV-1 vectors expressing foreign genes as anticancer therapeutic agents. Mol Pharm (2010) 0.76
In Reply: Volumetric Arc Therapy (RapidArc) vs Gamma Knife Radiosurgery for Multiple Brain Metastases: Not Only a Dosimetric Issue. Neurosurgery (2015) 0.75
In reply: volumetric arc therapy (RapidArc) vs Gamma Knife radiosurgery for multiple brain metastases. Neurosurgery (2015) 0.75
Ulceroglandular tularemia in a nonendemic area. South Med J (2007) 0.75
Bilateral metastatic renal hemangiopericytoma ten years after primary intracranial lesion. Int Braz J Urol (2006) 0.75
The history of neurosurgery at the University of Alabama at Birmingham. Neurosurgery (2014) 0.75